Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach

Eugene J. Koay, Alexander N. Hanania, William A. Hall, Cullen M. Taniguchi, Neal Rebueno, Sten Myrehaug, Katharine L. Aitken, Laura A. Dawson, Christopher H. Crane, Joseph M. Herman, Beth Erickson

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Purpose: To provide a detailed description of practical approaches to dose escalation in pancreatic cancer. Methods and Materials: The current paper represents an international collaborative effort of radiation oncologists from the MR-linac consortium with expertise in pancreatic dose escalation. Results: A 15-fraction hypofractionated intensity modulated radiation therapy (67.5 Gy in 15 fractions) and 5-fraction stereotactic body radiation therapy case (50 Gy in 5 fractions) are presented with information regarding patient selection, target volumes, organs at risk, dose constraints, and specific considerations regarding quality assurance. Additionally, we address barriers to dose escalation and briefly discuss future directions in dose escalation for pancreatic cancer, including particle therapy and magnetic resonance guided radiation therapy. Conclusions: This article on dose escalation for pancreatic cancer may help to guide academic and community based physicians and to serve as a reference for future therapeutic trials.

Original languageEnglish (US)
Pages (from-to)e495-e507
JournalPractical Radiation Oncology
Issue number6
StatePublished - Feb 18 2020

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach'. Together they form a unique fingerprint.

Cite this